| INTRODUCTION
Tumor necrosis factor (TNF) is a pleiotropic cytokine that mediates diverse physiological events including nuclear factor kappa B (NF-κB) activation, cell survival, and cell death, in the form of apoptosis and necroptosis. 1 Thus, defects in the regulation of TNF signaling contribute to a variety of pathological diseases, including cancer and long-lasting inflammatory diseases. 2 The pleiotropic nature of the TNF response largely depends on the sequential formation of different signaling complexes upon ligation to TNF receptor 1 (TNFR1), including a plasma membrane-bound primary complex and a cytoplasmic secondary complex, referred as complex-I and -II, respectively. 3, 4 Upon TNF ligation, TNFR1 initiates assembly of complex-I, which contains several adaptor proteins including TNFR1-associated death domain protein (TRADD), receptor interacting protein kinase 1 (RIPK1), TNFR-associated factor 2 (TRAF2), and/or TRAF5. 5 In complex-I, RIPK1 is conjugated via various linkages of ubiquitin (Ub) chains mediated by the E3 ligase cellular inhibitor of apoptosis proteins (cIAPs) and linear Ub chain assembly complex, and functions as a scaffold for the recruitment of transforming growth factor β activated kinase 1 (TAK1) or IκB kinase (IKK) complex (IKKα/β/NF-kappa-B essential modulator [NEMO] ). [6] [7] [8] This Ub network of RIPK1 plays an essential role in inducing canonical NF-κB activation to protect against apoptosis. [9] [10] [11] Alternatively, dissociation of complex-I from the plasma membrane results in the formation of a cytosolic complex-II consisting of TRADD, RIPK1, Fas-associated death domain protein (FADD), and caspase-8, leading to apoptosis. 3, 12 With sufficient expression of RIPK3 and concomitant inhibition of caspase-8, complex-II further develops into necrosome, leading to a series of phosphorylation events of RIPK1, RIPK3, and mixed lineage kinase-domain-like (MLKL) protein to induce necroptosis. [13] [14] [15] NF-κB-mediated transcriptional induction of pro-survival genes is a well-known protective mechanism against cell death that occurs as a late checkpoint. At present, it is believed that there are additional transcription-independent early cell death checkpoints regulated by phosphorylation of RIPK1. 16, 17 Consistent with this possibility, genetic deletion or pharmacological inhibition of TAK1 and IKKα/β resulted in further sensitization of cell death by activating RIPK1, independently of NF-κB activation. 18, 19 Subsequent biochemical analyses revealed that RIPK1 phosphorylation on Ser 321 or Ser 25 by TAK1 or IKKα/β in complex-I prevented the RIPK1-mediated assembly of the complex-II/necrosome and then inhibited apoptosis/necroptosis in an NF-κBindependent manner. 20, 21 Furthermore, it has been proposed that MAPK-activated protein kinase 2 (MK2) also induces RIPK1 phosphorylation in complex-I and protects against complex-II-mediated cell death. [22] [23] [24] It is now believed that RIPK1 phosphorylation by upstream kinases acts as an early cell death checkpoint to control the cytotoxic potential of TNF. Thus, development of pharmacological agents targeting RIPK1 phosphorylation may provide a novel strategy to promote the therapeutic efficacy of TNF in cancers and inflammatory diseases.
Plant-derived triterpenoids have been well studied with a wide range of pharmacological activities. 25 Pentacyclic triterpenoids in particular provide an excellent base from which new pharmacological agents can be developed for cancer therapy by modulating multiple signaling pathways related to apoptosis, autophagy, metastasis, and multidrug resistance. 26, 27 However, there has been little or no effort toward the efficacy of pentacyclic triterpenoids against TNF-targeted biologics, especially regarding RIPK1-dependent cell death. Previously, we isolated several types of novel pentacyclic triterpenoids from Rubia philippinensis (R. philippinensis) including lignans, cyclopeptides, and anthraquinones. 28, 29 In the present study, we examined 17 types of pentacyclic triterpenoids isolated from R. philippinensis, and identified 3-Oacetylrubianol C (3AR-C) as a novel arborinane triterpenoid with the ability of inducing RIPK1-dependent cell death by selectively inhibiting the catalytic activity of IKKβ independent of NF-κB. These findings provide the basis for further development of 3AR-C as a pharmacological agent for promoting the therapeutic efficacy of TNF.
| MATERIALS AND METHODS

| Preparation of 3AR-C
3-O-acetylrubianol C was discovered from our previous chemical study on Rubia philippinensis as a new natural-derived compound. 28 In brief, the column fraction D-5 (n-hexane-EtOAc 2:1 eluting fraction, 3.0 g) was prepared by silica gel column (20 × 20 cm) chromatography on methylene chloride (CH 2 Cl 2 )-soluble extract (50 g) of R. philippinensis, employing stepwise gradient solvents of n-hexane-EtOAc (20:1, 10:1, 5:1, 3:1, 2:1, 7 L each) and CHCl 3 -MeOH (8:1, 7 L). Further fractionation on the D-5 by reversed-phase C18 MPLC [stationary phase: SNAP cartridge KP-C18-HS 120 g, mobile phase: MeOH-H 2 O (10:90 → 100:0, 3 L)] resulted in the preparation of nine subfractions (D-5-1 to D-5-9). 3AR-C (t R 24.6 minutes, 30 mg) was purified from fraction D-5-5 (MeOH-H 
| Structure determination of 3AR-C
The molecular formula of the purified compound was deduced as C 30 9, 21.4) . The NMR spectroscopic data of the compound were similar to those of rubianol C, an arborinane triterpene bearing an acetyl group at C-28 isolated from Rubia yunnanensis, except for the presence of an additional acetyl functionality. The attachment of acetyl moiety at C-3 was revealed through HMBC spectroscopic data analysis. The β-orientation of the two acetyl functionalities was determined by the NOE correlations. On the basis of 1D-, 2D-NMR spectroscopic, and HR-ESI-MS data analyses, the structure was elucidated as 3-O-acetylrubianol C.
| Antibodies and reagents
All commercial antibodies were purchased from the following resources: anti-phospho-p65 Ser 536 ( 
| Cell culture and transfection
| Cell viability assay
Cells were plated onto 96-well plates at different cell densities, depending on cell type. After treatment, as described in the figure legends, cell viability assay was conducted utilizing Cell Titer-glo Luminescent Cell Viability Assay kit (Promega Co., Fitchburg, WI, USA), which measures cell viability based on adenosine triphosphate (ATP) levels present in live cells. Luminescent measurements were taken on a Tecan Infinite Plate Reader (Tecan group Ltd., Männedorf, Switzerland). Presented data were from at least three independent experiments. Representative images were also taken by an inverted microscope.
| Immunoblot analysis and isolation of complex-II and necrosome
After treatment with different conditions as described in the figure legends, cells were collected and lysed in M2 buffer (20 mM Tris, pH 7.6, 0.5% NP-40, 250 mM NaCl, 3 mM EDTA, 3 mM EGTA, 2 mM dithiothreitol, 0.5 mM PMSF, 20 mM β-glycerol phosphate, 1 mM sodium vanadate, and 1 µg/mL leupeptin). Fifty micrograms of cell lysates was fractionated by 10% or 6% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and visualized by enhanced chemiluminescence (GE Healthcare Life Sciences, Piscataway, NJ, USA). Densitometry were performed on scanned immunoblot images using an image J software. 30 The intensity for p-RIPK1 or c-FLIP L was determined relative to corresponding intensity of RIPK1 or actin, respectively. For immunopreciptation assays, the lysates were precipitated with an anti-caspase-8 antibody and protein A-agarose or G-sepharose beads by overnight incubation at 4°C. The beads were washed three times with M2 buffer, and the bound proteins were resolved in 10% SDS-PAGE for immunoblot analysis.
| In-vitro kinase assay
After treatment as described in the figure legends, cells were collected and lysed in M2 buffer. Whole cell lysates were immunopreciptated with an anti-NEMO antibody and protein G-sepharose beads overnight. The beads were washed with M2 buffer, and kinase assay was then performed in kinase assay buffer (20 mM HEPES at pH 7.5, 10 mM MgCl 2 , 1 mM DTT, 20 mM β-glycerol phosphate, 10 mM PNPP, 50 μM sodium vanadate, and 20 μM ATP) with the addition of [γ 32 P]-ATP and 1 μg of GST-IκBα as a substrate. After 30 minutes at 30°C, samples were analyzed by 10% SDS-PAGE, and the phosphorylated substrates were visualized by autoradiography.
| Statistical analysis
The quantitative data are presented as mean ± SE from at least three separate experiments that were performed in triplicate. The difference between groups were analyzed by Student's t test using SPSS software ver. 13.0 (SPSS, Inc). P < .05 is considered statistically significant.
| RESULTS
| Identification of 3AR-C as a potent sensitizer of TNF-mediated cell death and RIPK1 activation
To identify a novel small molecule with ability to promote TNF-mediated cell death, we used mouse embryonic fibroblasts (MEFs) as a model. First, we screened a set of pentacyclic triterpenoids purified from R. philippinensis that synergistically enhanced cell death in the presence of TNF (Supplementary Table 1 ). As expected, no evident cell death was observed in MEFs over 24 hours when treated with TNF alone (data not shown). Among 18 purified pentacyclic triterpenoids, four compounds (3AR-C, rubiarbonone C, oleanolic acid, and maslinic acid) led to a significant increase in cell death following TNF treatment, whereas these compounds themselves did not induce any cell death at a fixed concentration of 10 μM ( Figure 1A , Supplementary Table 1 ). Oleanolic acid and maslinic acid have been reported previously to potentiate TNF-mediated apoptosis by inhibiting NF-κB activation cancer cells 31, 32 ; whereas the other two pentacyclic arborinane triterpenoids (3AR-C and rubiarbonone C) have not been reported on TNF-mediated cell death. As phosphorylation of RIPK1 at Ser 166 has been established as a hallmark of RIPK1 activation to facilitate cell death, 33, 34 we then examined the effects of these pentacyclic triterpenoids on RIPK1 phosphorylation. In response to TNF, RIPK1 phosphorylation was marginally detectable in MEFs ( Figure 1B ). Of note, TNF-induced RIPK1 phosphorylation was drastically enhanced by pretreatment with 3AR-C, being consistent with its effect on promoting cell death upon TNFR1 ligation ( Figure 1B , Supplemental Table 1 ), suggesting that the enhancing potency of 3AR-C toward RIPK1 activation may be responsible for its sensitizing effect on TNF-mediated cell death. We also determined the chemical structure of 3AR-C, as shown in Figure 1C 
| 3AR-C induces RIPK1-dependent apoptotic and necroptotic cell death upon TNFR1 ligation in MEFs
Receptor interacting protein kinase 1 phosphorylation at Ser 166 is reportedly involved in two different modes of cell death (apoptosis and necroptosis) in cells with sufficient level of RIPK3 expression, such as MEFs. 35 To identify the modes of cell death sensitized by 3AR-C upon TNFR1 ligation, we pretreated MEFs with a pan-caspase inhibitor z-VAD-fmk (carbobenzoxy-valyl-alanyl-aspartyl-[Omethyl]-fluoromethylketone) (z-VAD) or a RIPK1 inhibitor necrostain-1 (Nec-1). As shown in Figure 2A , pretreatment with z-VAD markedly enhanced 3AR-C/TNF-induced cell death, while pretreatment with Nec-1 significantly abrogated 3AR-C/TNF-induced cell death. Moreover, we also examined the mode of cell death under in cells treated with 3AR-C/ TNF. Interestingly, there was evident cleavage of caspase-8 and -3 in MEFs treated with 3AR-C/TNF ( Figure 2B ), indicating apoptotic cell death. However, when the apoptotic pathway was blocked by z-VAD, the model of cell death F I G U R E 1 3AR-C upregulates TNF-induced cell death with RIPK1 phosphorylation at Ser 166 . A, Wild-type (WT) MEFs were preteated with a series of pentacyclic triterpenoids (10 μM) isolated from R. Philippinensis, cycloheximide (CHX, 10 μg/mL) or SM-164 (100 μM) for 30 minutes, followed by 15 ng/mL TNF for another 24 hours. Cell death was quantified using Cell Titer-glo Luminescent cell viability assay kit as described in Materials and Methods. Data were normalized to the rate of spontaneous cell death occurring in untreated cells. Each column shows the mean ± S.E. of three independent experiments. *P < .05, compared with the DMSO-treated group. B, WT MEFs were preteated with a series of pentacyclic triterpenoids (10 μM) isolated from R. Philippinensis, followed by 15 ng/mL TNF for 10 minutes. Whole cell lysates from each sample were separated by 10% SDS-PAGE, and immunoblotting was performed with the indicated antibodies (top). Relative density of p-RIPK1 was obtained by densitometry for corresponding RIPK1 at each lane (bottom). C, The chemical structure of 3-O-acetylrubianol-C (3AR-C) isolated from R. philippinensis was converted from apoptosis to necroptosis, evidenced by the strong protective effects of Nec-1 on cell death induced by 3AR-C/TNF+z-VAD ( Figure 2A ). Consistently, we observed enhanced RIPK1 phosphorylation accompanied by MLKL phosphorylation, a hallmark of necroptosis in cells treated with 3AR-C/TNF+z-VAD, which was completely blocked by Nec-1 ( Figure 2B ). Together, these results suggest that 3AR-C sensitizes TNF-mediated dual modes of cell death via upregulating RIPK1 activity in MEFs.
To directly determine whether 3AR-C's sensitization effect on TNF-mediated cell death is achieved by targeting RIPK1, we monitored the cytotoxic efficacy of 3AR-C in RIPK1 null (RIPK1 −/− ) MEFs. Consistent with a previous report, 36 TNF plus cycloheximide (TNF/CHX)-induced apoptosis in RIPK1−/− MEFs was comparable with the wild-type (WT) MEFs, which was not affected by Nec-1 ( Figure 2C were untreated or pretreated with Nec-1 (50 μM) for 30 minutes and then treated with 15 ng/mL TNF or in combination with 3AR-C (10 μM) and z-VAD-fmk (20 μM) for the indicated times and 12 hours, respectively. A, Cell viabilities were quantified as in Figure 1A . The values were represented as the mean ± S.E. of three independent experiments. B, Whole cell lysates from each sample were subjected to immunoblotting with the indicated antibodies. C-F, WT and RIPK1 −/− MEFs were untreated or pretreated with Nec-1 (50 μM) for 30 minutes, followed by 15 ng/ mL TNF with the various combinations with the indicated compounds (10 μM 3AR-C; 10 μg/mL CHX; 100 μM SM-164; 20 μM z-VAD-fmk for 12 hours. C, F, Cell death was quantified as in A. Each column shows the mean ± S.E. of three independent experiments. *P < .05, compared with the DMSO-treated group. D, Whole cell lysates from each sample were subjected to immunoblotting with the indicated antibodies. E, Cells were visualized using an inverted microscope. G, WT MEFs were treated with TNF (15 ng/mL) plus VAD-fmk (20 μM) or in combination with 3AR-C (10 μM) and SM-164 (100 μM) in the presence or absence of Nec-1 (50 μM). Whole cell lysates from each sample were subjected to immunoblotting with the indicated antibodies results suggest that 3AR-C potentiates dual modes of TNFmediated both apoptotic and necroptotic cell death by activating the kinase activity of RIPK1.
| 3AR-C suppresses IKK activation without affecting RIPK1 ubiquitination and TNFR1 signaling complex-I formation
Based on the common understanding that the recruitment of ubiquitinated RIPK1 into complex-I through interaction with adaptor proteins such as TRADD plays an essential role in TNF1-mediated cell death, 8 we next examined whether 3AR-C affects the formation of complex-I. As expected, treatment of cells with TNF led to immediate recruitment of TRADD, HOIP, IKKβ, and the hyper-ubiquitinated form of RIPK1 into TNFR1 ( Figure 3A, left panel) . However, unexpectedly, 3AR-C did not affect the recruitment of ubiquitinated RIPK1 or other adaptor proteins into TNFR1 following TNF treatment ( Figure 3A , right panel), suggesting that TNF-mediated cell death activated by 3AR-C was unlikely to be achieved through the regulation of RIPK1 recruitment into complex-I. To further probe the effect of 3AR-C at the level of complex-I, we subsequently examined the interaction between NEMO and ubiquitinated RIPK1. Similarly, we found that the interaction of ubiquitinated-RIPK1 with the IKKs (IKKα/β/NEMO) elicited by TNF was not affected by 3AR-C pretreatment ( Figure   3B ), confirming that 3AR-C does not affect the recruitment of ubiquitinated RIPK1 into complex-I. Interestingly, TNF-induced phosphorylation of IKKα/β was almost completely abolished by 3AR-C, even though the same amount of IKKs was precipitated in each sample. Such evidence thus suggests that the suppression of IKK phosphorylation by 3AR-C may be involved in its sensitization effect on RIPK1-mediated TNF cytotoxicity.
| 3AR-C exclusively suppresses
IKK-β phosphorylation in the canonical NF-κB pathway
To gain insight into the molecular mechanism underlying the sensitization effect of 3AR-C on RIPK1-mediated TNF cytotoxicity, we monitored the activation of early cell death checkpoint regulating kinases including IKKs, TAK1, and MK2 which are known to suppress RIPK1 activation by directly phosphorylating a number of Ser residues, including Ser 321 , Ser 25 and Ser 336 . [20] [21] [22] In a kinetic analysis, we found that 3AR-C suppressed IKKα/β phosphorylation whereas it resulted in remarkable increase of persistent RIPK1 phosphorylation at Ser 166 in response to TNF ( Figure 4A ). However, TNF-induced phosphorylation of TAK1 and MK2 was not affected by 3AR-C, thus excluding the possible involvement of TAK1 and MK2 in this process. Consistently, we also observed that 3AR-C potently inhibited not only IKK F I G U R E 3 3AR-C inhibits TNF-induced IKK phosphorylation without affecting RIPK1 ubiquitination and complex-I formation. WT MEFs were untreated or pretreated with 3AR-C (10 μM) for 30 minutes and then treated with 15 ng/mL TNF for the indicated times, and cell extracts were prepared as described in Materials and Methods. Cell extracts from each sample were subjected to immunoprecipitation with anti-TNFR1 (A) or anti-NEMO (B) antibodies. Immunoprecipitates were analyzed by immunoblotting with the indicated antibodies. A total of 1% of the cell extract volume (WCL) from each sample was used as input control activity toward an exogenous GST-IκBα fragment using an in vitro kinase assay ( Figure 4B ) but also the downstream events of the IKK signaling cascade (degradation of IκBα and phosphorylation of p65 at Ser 536 ) in response to TNF ( Figure 4C ). Importantly, the inhibitory effect of 3AR-C was specific to IKK, based on results that the phosphorylation of p65 at Ser 276 or mitogen activating protein kinases (MAPKs, JNK, ERK, and p-38) induced by TNF was not affected by 3AR-C ( Figure 4C ). Moreover, 3AR-C did not interfere with p65 phosphorylation at Ser 276 mediated by protein kinase C (PKC), whereas it drastically inhibited IκBα degradation and p65 phosphorylation at Ser 536 mediated by IKKs in response to PMA (Supplemental Figure S2A ). Having shown that 3AR-C inhibited IKK phosphorylation without affecting complex-I formation, it was predicted that 3AR-C may impose the same functional limits in the downstream tolllike receptor 4 (TLR4)/NF-κB pathway, because IKK acts as a common element for both TNF-and lipopolysacchardie (LPS)-induced NF-κB activation. 37 Consistent with this hypothesis, 3AR-C suppressed IKK phosphorylation and its downstream events (IκBα degradation and p65 phosphorylation at Ser 536 ) without altering ubiquitination or degradation of IRAK1 in response to LPS (Supplemental Figure S2B ). Furthermore, 3AR-C did not affect LPS-induced MAPKs phosphorylation, confirming that 3AR-C likely functions at the level of IKKs in suppressing NF-κB activation.
The IKKs has three components: two catalytic subunits, IKKα and IKKβ, and one regulatory subunit, NEMO. 38 To dissect the function of 3AR-C on the IKKs, we examined whether 3AR-C selectively affected phosphorylation of two F I G U R E 4 3AR-C selectively suppresses the phosphorylation of IKK-β in response to TNF. A-C, WT MEFs were untreated or pretreated with 3AR-C (10 μM) for 30 minutes and then treated with 15 ng/mL TNF for the indicated times. (A, C) Whole cell lysates from each sample were separated by 10% SDS-PAGE, and immunoblotting was performed with the indicated antibodies B, Cell extracts were subjected to immunoprecipitation with anti-NEMO antibody, and its activity was assayed by immune complex kinase assay as described in Materials and Methods (upper panel). The efficiency of immunoprecipitant of IKK complex was confirmed by immunoblotting with anti-IKKα antibody (lower panel). D, WT MEFs were untreated or pretreated with 3AR-C (10 μM) for 30 minutes and then treated with 15 ng/mL TNF for the indicated times. E, IKKα −/− and IKKβ −/− MEFs treated with TNF (15 ng/mL) or in combination with 3AR-C (10 μM) for 5 minutes. Cell extracts from each sample were separated by 6% SDS-PAGE, and immunoblotting was performed with the indicated antibodies kinase subunits, IKKα and IKKβ, respectively, by resolving the proteins using a 6% SDS-polyacrylamide gel. Notably, 3AR-C failed to suppress IKKα phosphorylation whereas it completely abrogated IKKβ phosphorylation in response to TNF ( Figure 4D ), suggesting that 3AR-C selectively antagonizes the catalytic activity of IKKβ. We further characterized the specific effect of 3AR-C on IKKβ using MEFs that are null of these kinases. In IKKα −/− cells, TNF treatment indeed elicited IKKβ phosphorylation, which was eliminated by 3AR-C ( Figure 4E, left panel) . In contrast, 3AR-C affected neither the basal level nor induced levels of IKKα phosphorylation by TNF in IKKβ −/− cells ( Figure 4E , right panel), confirming the specific inhibitory effect of 3AR-C against IKKβ. To further confirm this observation, we compared the ability of 3AR-C to regulate IKKβ-mediated canonical or IKKα-mediated noncanonical NF-κB activation. Consistently, 3AR-C efficiently suppressed TNF-like weak inducer of apoptosis (TWEAK)-induced p65 phosphorylation at Ser 536 (Supplemental Figure S3A ), which requires IKKβ activation. 38 In contrast, IKKα-mediated noncanonical NF-κB activation by TWEAK or LIGHT was not affected by 3AR-C, as shown by the processing of p100 to p52 and degradation of adaptor proteins including TRAF2 and TRAF3 (Supplemental Figure S3A,B) , confirming the specific inhibitory effect of 3AR-C on IKKβ.
In addition, we observed that 3AR-C pretreatment abrogated TNF-induced IKK phosphorylation in MEKK1 −/− and MEKK3 −/− MEFs (Supplemental Figure S4 ), suggesting that the inhibitory effect of 3AR-C on IKKβ of is not achieved through those upstream kinases of IKKs. Since it has been well-established that IKK could be activated via autophosphorylation, 39, 40 we examined the effect of 3AR-C on the oligomerization-mediated IKKβ autophosphorylation using ectopic expression of IKKβ. Being consistent with an earlier report, 40 overexpression of IKKβ resulted in significant IKK phosphorylation even in the absence of TNF, which was almost completely abolished by 3AR-C (Supplementary Figure  S5) . These results support the notion that 3AR-C is likely to inhibit at the step of IKKβ oligomerization and autophosphorylation without involving its known upstream kinases.
| Inhibition of IKKβ by 3AR-C contributes to RIPK1-dependent cell death independently of NF-κB in MEFs
Next, we attempted to determine whether the ability of 3AR-C to block IKKβ phosphorylation was responsible for enhancing the kinase activity of RIPK1. To do this, we compared the effect of 3AR-C on RIPK1 phosphorylation at Ser 166 to that of a known IKKβ specific inhibitor, TPCA-1 as a positive control. As expected, TNF-induced RIPK1 phosphorylation was only minimally detectable in WT MEFs, whereas it was prominent in IKKβ −/− MEFs ( Figure 5A ). Furthermore, in WT MEFs 3AR-C substantially enhanced TNF-induced RIPK1 phosphorylation, similar to the effect of TPCA-1 ( Figure 5A, left panel) . In contrast, in IKKβ −/− MEFs, neither 3AR-C nor TPCA-1 was able to upregulate TNF-induced RIPK1 phosphorylation ( Figure 5A, right panel) , confirming that IKKβ is implicated in the effect of 3AR-C on RIPK1.
To determine whether RIPK1 activation by 3AR-C regulates TNF-mediated cell death independently of transcriptional activation of NF-κB, we tested the susceptibility of cells to treatment with 3AR-C/TNF in the presence of cycloheximide (CHX), which blocks de novo protein synthesis of NF-κB target genes. As shown in Figure 5B , significant sensitization to CHX/TNF (CT)-induced cell death was observed in 3AR-C pretreated cells, and this sensitizing effect was completely protected by Nec-1. In contrast, Nec-1 failed to protect against cell death after CT treatment ( Figure 5B) , consistent with the well-established concept that CT-induced cell death occurs independently of RIPK1. 18, 34, 36 Moreover, pretreatment of p65 −/− MEFs with 3AR-C significantly enhanced TNF-induced cell death ( Figure 5C ), similar to WT MEFs. In contrast, in IKKβ −/− MEFs, 3AR-C failed to enhance TNF-induced cell death ( Figure 5D ). Taken together, these results suggest that the sensitization effect of 3AR-C on TNF-mediated cell death via IKKβ inhibition and RIPK1 activation is independent of NF-κB.
| IKKβ inhibition by 3AR-C drives
RIPK1-dependent cell death under cellular FLICE inhibitory protein (c-FLIP) depletion in human cancer cells
Although the recent discovery of RIPK1-dependent cell death by inhibiting IKKβ widens the therapeutic efficacy of TNF, its clinical implications in human cancer remain unclear and controversial. 18, [41] [42] [43] To establish the clinical relevance of our findings, we assessed whether 3AR-C potentiates the cytotoxicity of TNF in multiple types of human cancer cells. In contrast to its effects in MEFs under the same conditions, 3AR-C did not induce evident cell death in all human cancer cells tested in the presence of TNF or z-VAD up to 24 hours ( Figure 6A ), despite 3AR-C or TPCA-1 efficiently preventing TNF-induced IKKβ phosphorylation in these cells (data not shown).
To obtain insight into the insensitivity of human cancer cells to 3AR-C, we carefully checked expression levels of several key anti-apoptotic proteins in TNF signaling pathway that are known to be involved in either IKKβdependent or transcription-dependent cell death checkpoint in human cancer cells. Interestingly, whereas 3AR-C or TPCA-1 was sufficient to suppress inducible expression of anti-apoptotic proteins including A20, cIAP1, and MnSOD in response to TNF, the expression levels of the long isoform of cellular FLIP (c-FLIP L ) remained stable in HeLa cells ( Figure 6B ). Consistently, no apoptotic phenotypes, including cleaved forms of caspase-8, caspase-3, Bid, and PARP were detected in HeLa cells treated with 3AR-C/ TNF or TPCA-1/TNF. In contrast, treatment of HeLa cells with CT resulted in strikingly decreased levels of c-FLIP L , which was associated with significant apoptotic cell death ( Figure 6B ). Although different cFLIP isoforms may have a different impact on the TNF-mediated cell death at the level of complex-II or Ripoptosome, 44 it is possible that substantial levels of c-FLIP L contributes to the resistance of human cancer cells to the sensitization effect of 3AR-C on TNF-mediated cell death in human cancer cells. Furthermore, given that the expression of basal A20 levels upon TNF/TPCA-1 or TNF/3AR-C treatment was comparable to a similar extent as did TNF/CHX ( Figure 6B) , it is believed that suppression of inducible level of A20 expression by 3AR-C or TPCA-1 is unlikely be an important factor in regulating TNF-mediated apoptosis.
Next, we systematically compared the c-FLIP L expression levels in all the human cancer cells tested in this study and found that one human kidney carcinoma cell line A498 with exceptionally low level of c-FLIP L (Figure 6C ). Subsequently, we compared the susceptibilities of cell death by 3AR-C/TNF using a pair of human kidney carcinoma cell lines (A498 and Caki cells) harboring different expression levels of c-FLIP L . As expected, whereas 3AR-C was not effective in sensitizing TNF-mediated cell death in Caki cells, remarkable sensitization to cell death by 3AR-C/TNF was observed in A498 cells ( Figure 6D ). Notably, 3AR-C/TNF-induced cell death was even more extensive under the caspase-blocked condition with z-VAD, and this enhanced cell death was completely prevented by Nec-1 in A498 cells. Consistent with these findings, knockdown of endogenous c-FLIP L in Caki cells led to drastic sensitization of cell death in response to 3AR-C/TNF or 3AR-C/TNF/z-VAD ( Figure 6E ). All these results collectively support the notion that in human cancer cells c-FLIP L is a key factor in inhibiting cell death induced by 3AR-C/TNF.
| 3AR-C and bromodomain and extraterminal domain (BET) inhibitor JQ1 function synergistically to promote RIPK1-dependent cell death by inducing formation of complex-II and necrosome
It has been reported that BET inhibitor JQ1 is able to downregulate c-FLIP L and sensitizes death receptor-mediated F I G U R E 5 RIPK1-mediated apoptosis and necroptosis by 3AR-C is independent of NF-κB. A, WT and IKKβ −/− MEFs were treated with TNF (15 ng/mL) or in various combinations with indicated compounds (10 μM 3AR-C; 1 μM TPCA-1; 50 μM Nec-1) for 30 minutes. Whole cell lysates from each sample were subjected to immunoblotting with the indicated antibodies. B-D, WT or MEFs of indicated genotypes were treated with TNF (15 ng/mL) or in various combinations with indicated compounds (10 μg/mL CHX; 50 μM Nec-1; 10 μM 3AR-C) for the indicated times. Cell death was quantified as in Figure 1A . The values were represented as the mean ± S.E. of three independent experiments. *P < .05, compared with the CHX plus TNF (CT)-treated group. # P < .05, compared with the TNF (T)-treated group apoptosis in diverse types of cancers. 45, 46 Thus, we examined whether downregulation of c-FLIP L by JQ1 was able to affect the sensitization effect of 3AR-C on RIPK1-dependent cell death in human cancer cells. Whereas JQ1 and TNF alone minimally elicited cell death, the combination of JQ1 and TNF (JQ1/TNF) exerted synergic effects on cell death in multiple types of human cancer cell lines ( Figure 7A ). Importantly, 3AR-C was able to markedly enhance cell death induced by JQ1/TNF and such cell death was significantly protected by Nec-1. Consistent with these observations, a drastic and consistent changes in RIPK1 phosphorylation were found in cells after combined treatment with JQ1, compared to treatment with 3AR-C/TNF, despite the comparable extent of RIPK1 ubiquitination observed in those cells ( Figure 7B ).
We next assessed whether 3AR-C regulates TNFinduced cytotoxicity (apoptosis or necroptosis) by acting on the site of complex-II or necrosome formation when c-FLIPL L is downregulated by JQ1. As expected, TNFmediated cytotoxicity was drastically increased after the Figure 7C) . A subsequent immunoprecipitation assay using an anti-caspase-8 antibody revealed that treatment of HT-29 cells with 3AR-C/TNF in the absence of JQ1 led to recruitment of c-FLIP L to the isolated complex-II, whereas complex-II-bound RIPK1 was only weakly detected ( Figure 7D, left panel) . In contrast, combined treatment with JQ1 and 3AR-C/TNF resulted in a drastic increase of complex-II formation, concomitant with cleaved forms of RIPK1 ( Figure 7D, right panel) . More importantly, under this condition, the activation of procaspase-8 within complex-II proceeded to completion in a time-dependent manner, as shown by the appearance of its active p18 subunit. Furthermore, in the presence of JQ1, 3AR-C was able to greatly sensitize necroptotic cell death induced by TNF/z-VAD, and such enhanced necroptosis was almost completely prevented by Nec-1 ( Figure 7E ). Consistently, we found that the recruitment of phosphorylated forms of RIPK1, RIPK3, and MLKL into caspase-8 were detectable in HT-29 cells, which peaked at 6-12 h after treatment with 3AR-C/TNF/z-VAD in the presence of JQ1 ( Figure 7F ). Figure 1A . Each column shows the mean ± S.E. of three independent experiments. *P < .05, compared with TNF-transfected group. # P < .05, compared with the 3AR-C and TNF (3AR-C/T)-treated group. B, HT-29 cells were pretreated with 3AR-C (10 μM) and/or JQ1 (1 μM) for 30 minutes and/or 24 hours, respectively, and followed by TNF (15 ng/mL) for the indicated times. Whole cell extracts were subjected to immunoblotting with the indicated antibodies. C, E, HT-29 cells were treated with TNF (15 ng/mL) or in combination with the indicated compounds (10 μM 3AR-C; 50 μM Nec-1; 20 μM z-VAD-fmk) in the absence or presence of JQ1 (1 μM) pretreatment for 24 hours for the indicated times. Cell death was quantified as in A. The values were represented as the mean ± S.E. of three independent experiments. *P < .05, compared with the 3AR-C/T-and 3AR-C/T/Z-treated group. # P < .05, compared with the 3AR-C/T+JQ1-and 3AR-C/T/Z+JQ1-treated group. D, F, After 24 hours pretreatment with JQ1 (1 μM), HT-29 cells were treated with 3AR-C/T (10 μM 3AR-C and 15 ng/mL TNF) D, and 3AR-C/T/Z (3AR-C/T and 20μM z-VAD-fmk) for the indicated times in the absence or presence of Nec-1 (50 μM). F, Cell extracts from each sample were subjected to immunoprecipitation with anti-caspase-8 antibody and immunoblotted with indicated antibodies. A total of 1% of the cell extract volume (WCL) from each sample was used as input control. The asterisk indicates either the cleaved products of RIPK1, caspase-3, and PARP or phosphorylated forms of RIPK3 These observations collectively suggest that in multiple types of human cancer cells, downregulation of c-FLIP L expression is required for the sensitization effect of 3AR-C on TNF-mediated cell death via formation of complex-II or necrosome.
| DISCUSSION
Receptor interacting protein kinase 1 has emerged as an essential molecule involved in regulating both cell survival and cell death (13.17) . It is now known that RIPK1 undergoes a large array of posttranslational modifications including ubiquitination, phosphorylation, and acetylation that regulate cell fate by deciding between life and death. [9] [10] [11] 47 In complex-I, ligation of TNFR1 induces various types of RIPK1 ubiquitination, which plays an essential role in recruiting the IKKs (IKKα/β/NEMO) and subsequent transcriptional induction of NF-κB-dependent pro-survival genes including c-FLIP, A20, and cIAP2. [6] [7] [8] 48 In addition, transient phosphorylation of RIPK1 at Ser 25 by IKKs prevents its dissociation from complex-I, and suppresses its Ser 166 -autophosphorylationdependent association with FADD to initiate formation of complex-II/necrosome which functions as transcription-independent players in TNF-induced cell death. 18, 22, 49, 50 The kinase activity of RIPK1 is required for activation of RIPK3 that plays an essential role in necroptosis induction. 14, 15 Thus, discovery of small molecules regulating RIPK1 phosphorylation provides a basic research tool and substantiates the overall importance of early cell death checkpoint controlling apoptosis and necroptosis. As part of our ongoing search for bioactive compounds as novel anti-cancer agents, 3AR-C isolated from R. philippinesis was identified as a potent inducer of RIPK1-dependent cell death using a MEF-based screening system.
One interesting finding from this study was that 3AR-C specifically targets IKKβ. The disparity in the inhibitory potency of 3AR-C against IKKα and IKKβ was evidenced by the following observations: (i) 3AR-C did not affect TNFinduced IKKα phosphorylation in WT and IKKβ −/− cells, whereas the phosphorylation of IKKβ was almost completely impaired in IKKα −/− cells ( Figure 4C,D) , and (ii) 3AR-C exclusively inhibited IKKβ-mediated p65 phosphorylation at Ser 536 but not IKKα-mediated proteolytic processing of p100, TRAF2, and TRAF3 in TWEAK-or LIGHT-treated cells (Supplemental Figure S3 ). Furthermore, 3AR-C did not function as a general NF-κB inhibitor because it did not inhibit PKC-induced p65 phosphorylation at Ser 276 (Supplemental Figure S2) . Moreover, by inhibiting the kinase activity of IKKβ without affecting complex-I formation, 3AR-C was able to enhance TNF-induced RIPK1 phosphorylation at Ser 166 , which is essential in activating its cytotoxic potential in RIPK1-dependent cell death. Consistent with this possibility, we also found that, similar to the specific IKKβ inhibitor TPCA-1, 3AR-C efficiently upregulated TNFinduced RIPK1 phosphorylation at Ser 166 in WT MEFs, but not in the in IKKβ −/− cells ( Figure 5 ). In this regard, we hypothesize that 3AR-C likely mediates both RIPK1-dependent apoptotic and necroptotic cell death by exclusively antagonizing IKKβ. However, the mechanism by which 3AR-C selectively targets IKKβ to regulate its catalytic activity is a subject for further investigation.
Previous studies reported that upstream kinases such as TAK1, NIK, MEKK1 and MEKK3 can activate IKKβ by catalyzing the phosphorylation of serine residues within its activation loop (Ser 177 and Ser 181 ). 51, 52 In addition, IKKβ also can undergo oligomerization and subsequent autophosphorylation that enables IKKβ to activate itself. 39, 40, 53 In this study, we found that 3AR-C affected neither NIK accumulation (Supplementary Figure S3 ) nor TAK1 phosphorylation ( Figure 4A ) in response to TWEAK or TNF. Moreover, 3AR-C efficiently impaired IKKβ phosphorylation by ectopic its expression in the absence of TNF (Supplementary Figure  S5 ). Such findings thus suggest that 3AR-C may function to disrupt the oligomerization and autophosphorylation of IKKβ without affecting its upstream kinases. This interpretation was further supported by the observations that the inhibitory effect of 3AR-C on IKKβ was normal in MEKK1-or MEKK3-deficient MEFs (Supplementary Figure S4) . Future study is needed to understand the structural basis for the dynamic interaction between 3AR-C and IKK subunits.
The participation of IKKβ in TNF-mediated cell death could occur at a point of either NF-κB-dependent or -independent. 16, 17 In this study, we found that 3AR-C sensitized RIPK1-dependent apoptosis and necroptosis upon TNFR1 ligation by inhibiting IKKβ. Consistently, we also found that such dual modes of cell death by 3AR-C/TNF were completely abrogated in RIPK1-null MEFs (Figure 2 ). Furthermore, 3AR-C significant sensitized TNF-induced cell death in WT and p65 −/− MEFs but not in IKKβ −/− MEFs ( Figure 5 ). These observations clearly suggest that IKKβ inhibition by 3AR-C functions in controlling the early cell death checkpoint in a NF-κB-independent manner. However, given that IKKβ plays a pivotal role in NF-κB activation, it is also possible that transcriptional suppression of NF-κB-mediated pro-survival genes by 3AR-C may involve in its sensitizing effect against cell death.
At present it still remains controversial whether IKKβ inhibition by small molecules for inducing RIPK1dependent cell death could be used for therapeutic purpose in human diseases. Indeed, the IKKβ-NF-κB signaling axis does play a pivotal role in inflammation and cell survival, and thus complete IKKβ deficiency was embryonic lethal in mouse. 54, 55 However, lymphocyte development and the apoptotic phenotype were normal in patients with severe combined immunodeficiency, despite loss of IKKβ function, 56, 57 suggesting that other factors may contribute to prevent RIPK1-dependent cell death by the inhibition of IKKβ in human cancer cells. Accordingly, in this study, we found that 3AR-C/TNF treatment failed to induce RIPK1dependent cell death in various types of human cancer cell lines, even though it sufficiently protected against the induction of anti-apoptotic genes ( Figure 6 ). Given the fact that interactions between c-FLIP L and caspase-8 occurred in response to 3AR-C/TNF in HT-29 cells ( Figure 7D, left  panel) , it is likely that c-FLIP L, when recruited to complex-II, is responsible for the protection against RIPK1dependent cell death in cancer cells. This conclusion was further supported by the fact that, under the genetic or pharmacological depletion of c-FLIP L , 3AR-C efficiently shifted the TNF response to cell death by facilitating the formation of either complex-II or necrosome (Figure 7) .
Based on these results, we propose that the intracellular levels of c-FLIP L in many human cancer cells is an important factor in control of TNF-mediated cell death by competing with and limiting the cytotoxic potential of RIPK1 via IKKβ inhibition. Further studies elucidating the role of c-FLIP L in RIPK1 phosphorylation either in vitro or in vivo in human cancer specimens will facilitate the development of IKKβ inhibitors such as 3AR-C for the treatment of human cancers.
